Trial period	Screening	Randomized treatment period				FU period
Visit (day of treatment)	1 (−21 to −4)	2 (1)	3 (43 ± 7)	4/End of treatment (85 ± 7)	Early DC on visit	FU visit (±7) or DC + 7 days
Demographics	X
Vital signs	X	X	X	X	X	X
HbA1c		X		X	X
eGFR (CKD‐EPIcr formula)	X	X	X	X	X	X
Safety lab	X	X	X	X	X	X
ECG	X			X	X
NT‐proBNP	X	X	X	X	X
6‐min walk test	X	X	X	X	X
Adverse events	X	X	X	X	X	X
KCCQ		X	X	X	X
CHQ‐SAS		X	X	X	X
Clinical Congestion Scorea		X	X	X	X
Patient Global Impression of Severity of heart failure symptoms		X	X	X	X
Patient Global Impression of Severity of dyspnoea		X	X	X	X
Patient Global Impression of Change in heart failure symptoms			X	X	X
Patient Global Impression of Change in dyspnoea			X	X	X
Clinician Global Impression of Severity of CHF		X	X	X	X
Clinician Global Impression of Change in CHF severity			X	X	X
NYHA classification	X	X	X	X	X
HCRU		X	X	X	X

CHF, chronic heart failure; CHQ‐SAS, Chronic Heart Failure Questionnaire Self‐Administered Standardised format; CKD‐EPIcr, Chronic Kidney Disease‐Epidemiology Collaboration creatinine equation; DC, discontinuation; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; FU, follow‐up; HbA_1c, glycated haemoglobin; HRCU, health care resource utilisation; KCCQ, Kansas City Cardiomyopathy Questionnaire; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide; NYHA, New York Heart Association.

Patient's congestion will be assessed using a clinician‐based outcome assessment of orthopnoea, fatigue, jugular venous distention (as assessed by the investigator), and oedema. Each category will be assessed through a four‐measure questionnaire that will be further converted to a standardised 4‐point scale ranging from 0 to 3 as shown.

^aClinical Congestion Score.